BDSX Stock Overview
Operates as a diagnostic solutions company. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Biodesix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$2.04 |
| 52 Week Low | US$0.17 |
| Beta | 1.17 |
| 1 Month Change | -45.14% |
| 3 Month Change | -69.42% |
| 1 Year Change | -80.88% |
| 3 Year Change | -79.65% |
| 5 Year Change | n/a |
| Change since IPO | -97.65% |
Recent News & Updates
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers
May 15
It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year
May 14Recent updates
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers
May 15It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year
May 14Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding
Apr 19
Sales Force Expansion And CLARIFY Study Will Boost Test Adoption
Expansion of sales force and test adoption, along with CLARIFY study results, are expected to drive revenue growth and improve margins.It's Down 30% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
Mar 05The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27%
Jan 19With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
Nov 21Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?
Sep 24Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear
Jun 12With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
Mar 03Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce
Jan 04It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
Jul 16A Second Look At Biodesix
Oct 18Biodesix expects Q3 revenue above the consensus
Oct 11Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M
Aug 04Biodesix: Bad Diagnosis
May 26Shareholder Returns
| BDSX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -18.9% | -7.9% | 2.9% |
| 1Y | -80.9% | -20.2% | 11.9% |
Return vs Industry: BDSX underperformed the US Healthcare industry which returned -20.9% over the past year.
Return vs Market: BDSX underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| BDSX volatility | |
|---|---|
| BDSX Average Weekly Movement | 20.4% |
| Healthcare Industry Average Movement | 7.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: BDSX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BDSX's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 273 | Scott Hutton | www.biodesix.com |
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions.
Biodesix, Inc. Fundamentals Summary
| BDSX fundamental statistics | |
|---|---|
| Market cap | US$43.97m |
| Earnings (TTM) | -US$40.42m |
| Revenue (TTM) | US$74.46m |
0.6x
P/S Ratio-1.1x
P/E RatioIs BDSX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDSX income statement (TTM) | |
|---|---|
| Revenue | US$74.46m |
| Cost of Revenue | US$16.10m |
| Gross Profit | US$58.36m |
| Other Expenses | US$98.78m |
| Earnings | -US$40.42m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 78.38% |
| Net Profit Margin | -54.28% |
| Debt/Equity Ratio | 331.9% |
How did BDSX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 03:32 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biodesix, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| William Bonello | Craig-Hallum Capital Group LLC |